A treatment device such as a biliary stent, capable of effectively and continuously inhibiting biofilm formation, and a biofilm formation inhibitor suitable for coating on the treatment device by killing all bacteria including E. coli and by suppressing the growth of these bacteria, are provided. A biofilm formation inhibitor having an effective amount of catechin for inhibiting biofilm formation and a carrier that is suitable for adhesion of said catechin to a treatment device to be placed in the living body, are provided.

Claims

10 · 2 independent · depth 2

10 granted claims

›1.independentA biofilm formation inhibitor comprising an effective amount of an isolated catechin for inhibiting biofilm formation by E. Coli and a hydrophilic bio…+4

›4.independentA biliary stent to be placed in a living body, wherein an effective amount of an isolated catechin for inhibiting biofilm formation by E. Coli is coat…+4

Classifications

5 codes

IPC · International Patent Classification

Section A — Human necessities

A61F2/00
A61F2/06

USPC · US Patent Classification

623/1.42623/1.46424/423

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

6.3 y

2,295 days filing → grant

Office actions

non-final + final

Responses

2 RCE

Examiner

Thomas J Sweet

art unit 3738 · TC 3700

Law firm

Law firm · Log in to unlock

Citations: 23 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20090099646 A1	16 Apr 2009

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.